Real-world efficacy and safety of pyrotinib in patients with HER2-positive metastatic breast cancer: A prospective real-world study

Background: Pyrotinib, a novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor, shows encouraging anticancer activity and acceptable tolerability in multiple phase II and phase III randomized clinical trials, but the real-world data of pyrotinib, especially the outcomes in HER2-positive metast...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Qiongwen, He, Ping, Tian, Tinglun, Yan, Xi, Huang, Juan, Zhang, Zhang, Zheng, Hong, Zhong, Xiaorong, Luo, Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070865/
https://www.ncbi.nlm.nih.gov/pubmed/37025489
http://dx.doi.org/10.3389/fphar.2023.1100556

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070865/
https://www.ncbi.nlm.nih.gov/pubmed/37025489
http://dx.doi.org/10.3389/fphar.2023.1100556

Ejemplares similares